Artel is the global technology leader in ultra low volume liquid delivery measurement and quality assurance. The company develops and manufactures the most accurate, precise and easy-to-use systems available for ensuring liquid delivery data integrity and NIST-traceable results in life sciences laboratories. Artel innovations help laboratories improve processes and increase productivity, enhance product quality, and address compliance challenges.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

SYNLOGIC ANNOUNCES SYNTHETIC BIOTIC FOR GOUT DEVELOPED IN PARTNERSHIP WITH GINKGO BIOWORKS

Ginkgo Bioworks | August 12, 2022

news image

Synlogic, Inc. a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and ...

Read More

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

news image

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More

MedTech

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

news image

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More

Diagnostics

PHENOMIX SCIENCES ANNOUNCES FIRST OBESITY BIOBANKING REGISTRY AND OUTCOMES STUDY FOR PRECISION NUTRITION AND OBESITY

Phenomix Sciences | May 27, 2022

news image

Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first t...

Read More
news image

Industrial Impact

SYNLOGIC ANNOUNCES SYNTHETIC BIOTIC FOR GOUT DEVELOPED IN PARTNERSHIP WITH GINKGO BIOWORKS

Ginkgo Bioworks | August 12, 2022

Synlogic, Inc. a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and ...

Read More
news image

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More
news image

MedTech

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More
news image

Diagnostics

PHENOMIX SCIENCES ANNOUNCES FIRST OBESITY BIOBANKING REGISTRY AND OUTCOMES STUDY FOR PRECISION NUTRITION AND OBESITY

Phenomix Sciences | May 27, 2022

Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us